FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4371-4374

  Hibi, Kenji ^a   Mizukami, Hiroki ^a   Saito, Mitsuo ^a   Kigawa, Gaku ^a   Nemoto, Hiroshi ^a   Sanada, Yutaka ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Colorectal cancer; FBN2; Hepatic metastasis; Methylation

Indexed keywords

DNA; FIBRILLIN 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA; DNA METHYLATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED;

EID: 84867813233     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650, 1977. (Pubitemid 8051621)
2. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46: 318-322, 1989. (Pubitemid 19216753)
3. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D and Jen J: Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 58: 1405-1407, 1998. (Pubitemid 28193600)
4. Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ and Stroun M: A prospective study of KRAS mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4: 271-275, 1998. (Pubitemid 28122737)
5. Ito S, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S and Nakao A: Detection of tumor DNA in serum of colorectal cancer patients. Jpn J Cancer Res 93: 1266-1269, 2002. (Pubitemid 36032991)
6. Uemura T, Hibi K, Kaneko T, Takeda S, Inoue S, Okochi O, Nagasaka T and Nakao A: Detection of oncogenic mutation in the plasma DNA of pancreatic cancer patients. J Gastroenterol 39: 56-60, 2004. (Pubitemid 38208243)
7. Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, Ito K, Akiyama S and Nakao S: Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 94: 429-431, 2001. (Pubitemid 32906076)
8. Okochi O, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T and Nakao A: Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res 8:2875-2878, 2002. (Pubitemid 35025733)
9. Myohanen SK, Baylin SB Herman JG: Hypermethylation can selectively silence individual p16INK4A alleles in neoplasia. Cancer Res 58: 591-593, 1998. (Pubitemid 28099461)
10. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB and Herman JG: Hypermethylation-associated inactivation of p14 (ARF) is independent of p16 (INK4A) methylation and p53mutational status. Cancer Res 60: 129-133, 2000. (Pubitemid 30058742)
11. Hibi K, Nakayama H, Kanyama Y, Kodera Y, Ito K, Akiyama S and Nakao A: Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer 104: 433-436, 2003. (Pubitemid 36323912)
12. Fujitake S, Hibi K, Okochi O, Kodera Y, Ito K, Akiyama S and Nakao A: Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J Gastroenterol 39: 120-124, 2004. (Pubitemid 38325187)
13. Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S and Nakao A: CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer 90: 1030-1033, 2004. (Pubitemid 38495824)
14. Nakayama H, Hibi K, Taguchi M, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S and Nakao A: Molecular detection of p16promoter methylation in the serum of colorectal cancer patients. Cancer Lett 188: 115-119, 2002. (Pubitemid 35292337)
15. Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, Nakajima T, Nakagawara A and Kimura H: Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer 50: 43-49, 2005. (Pubitemid 41297468)
16. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, Ito K and Takagi H: Loss of H19 imprinting in esophageal cancer. Cancer Res 56: 480-482, 1996. (Pubitemid 26048601)
17. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, Akiyama S and Nakao A: Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 7: 3135-3138, 2001. (Pubitemid 32963835)
18. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999. (Pubitemid 29062958)
19. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM and Johnson PJ: Detection of aberrant p16methylation in the plasma and serum of liver cancer patients. Cancer Res 59: 71-73, 1999. (Pubitemid 29062959)
20. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S and Nakao A: Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 105: 491-493, 2003. (Pubitemid 36578552)
21. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895, 2000. (Pubitemid 30129522)
22. Vogelstein B and Kinzler KW: Digital PCR. Proc Natl Acad Sci USA 96: 9236-9241, 1999. (Pubitemid 29374738)